Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Documenti analoghi

• Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48‐ADC) combined immunotherapy in patients with muscle‐invasive bladder cancer: A multi‐center real‐world study
  di: Jiao Hu, et al.
  Pubblicazione: (2025)
• Efficacy and safety of camrelizumab combined with oxaliplatin and S‐1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single‐arm study
  di: Wen‐Jin Zhong, et al.
  Pubblicazione: (2024)
• Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial
  di: Yuzhou Zhao, et al.
  Pubblicazione: (2024)
• Efficacy and safety of Brucea javanica oil soft capsules combined with oral chemotherapy for maintenance therapy in advanced gastric cancer
  di: Yingying Kou, et al.
  Pubblicazione: (2025)
• Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial
  di: Xiaochu Man, et al.
  Pubblicazione: (2024)